Clene presents data showing CNM-Au8 boosts brain energy in MS patients

Clene Inc. has presented clinical results from its REPAIR trials at the ECTRIMS 2025 meeting in Barcelona, asserting that treatment with its investigational therapy CNM-Au8 improved brain energy metabolism in patients with multiple sclerosis (MS). According to the company, combined Phase 2 data across relapsing MS, non-active progressive MS, and Parkinson’s disease cohorts showed a […] The post Clene presents data showing CNM-Au8 boosts brain energy in MS patients appeared first on Longevity.Technology.